-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SJ2ENbF5hYnew0Hl/eprHnTISoZ8c9wXHxxgXAnSc1/QXpjYxkIGz/VhWACz/lln zzqk6r2ufKx3JSdxS1V/Ow== 0001005477-03-004013.txt : 20031002 0001005477-03-004013.hdr.sgml : 20031002 20031002210506 ACCESSION NUMBER: 0001005477-03-004013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030930 FILED AS OF DATE: 20031002 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PARKINSON ROBERT L JR CENTRAL INDEX KEY: 0001168252 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12957 FILM NUMBER: 03926144 BUSINESS ADDRESS: STREET 1: ENZON INC STREET 2: 20 KINGSBRIDGE RD CITY: PISCATAWAY STATE: NJ ZIP: 08854 BUSINESS PHONE: 8474441449 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENZON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000727510 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222372868 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 685 ROUTE 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 7329804500 MAIL ADDRESS: STREET 1: C/O DORSEY & WHITNEY LLP STREET 2: 250 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10177 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICAL INC DATE OF NAME CHANGE: 20021210 FORMER COMPANY: FORMER CONFORMED NAME: ENZON INC DATE OF NAME CHANGE: 19920703 4 1 edgar123.xml FORM 4 X0201 4 2003-09-30 0 0000727510 ENZON PHARMACEUTICALS INC enzn 0001168252 PARKINSON ROBERT L JR C/O ENZON PHARMACEUTICALS, INC. 685 ROUTE 202/206 BRIDGEWATER NJ 08807 1 0 0 0 Common Stock Right 0 2003-09-30 4 A 0 301 0 A 2004-01-01 2004-06-30 Common Stock 301 301 D Securities granted by Enzon Pharmaceuticals, Inc. pursuant to Enzon's 2001 Incentive Stock Plan as compensation for service as an Independent Director during the quarter ended September 30, 2003 and qualified under Rule 16b-39(d). The value of the compensation was $3,500. In the spring of 2004, each Common Stock right will be exchanged for one share of Common Stock; provided, however, Mr. Parkinson will be entitled to elect to receive cash for up to 50% of these rights, with the price per right being $11.64, the fair market value of Enzon's common stock on September 30, 2003. On a 1-for-1 basis. /s/ Kenneth J. Zuerblis (Attorney in Fact) 2003-10-02 -----END PRIVACY-ENHANCED MESSAGE-----